Research Progress on Structure-Activity Relationship of 1,8-Naphthalimide DNA Chimeras Against Tumor

Hai-yang Zhang,Li-li Han,Hong-yi Wu,Xiang-xiang Xu,Meng-bin Yu,Gao-yun Chen,Xiu-li Qi
DOI: https://doi.org/10.1177/15330338231225861
2024-01-17
Technology in Cancer Research & Treatment
Abstract:Technology in Cancer Research &Treatment, Volume 23, Issue , January-December 2024. The development of 1,8-naphthalimide derivatives as cell probes, DNA targeting agents, and anti-tumor drugs is one of the research hotspots in the field of medicine. Naphthalimide compounds are a kind of DNA embedder, which can change the topological structure of DNA by embedding in the middle of DNA base pairs, and then affect the recognition and action of topoisomerase on DNA. Aminofide and mitonafide are the first 2 drugs to undergo clinical trials. They have good DNA insertion ability, can embed DNA double-stranded structure, and induce topoisomerase II to cut part of pBR322DNA, but not yet entered the market due to their toxicity. In this paper, the design and structure-activity relationship of mononaphthalimide and bisaphthalimide compounds were studied, and the relationship between the structure of naphthalimide and anti-tumor activity was analyzed and discussed. It was found that a variety of structural modifications were significant in improving anti-tumor activity and reducing toxicity.
oncology
What problem does this paper attempt to address?